Survival of patients with deficient mismatch repair metastatic colorectal cancer in the pre-immunotherapy era

被引：21

作者：

Wensink, G. Emerens ^{[1
]}

Elferink, Marloes A. G. ^{[2
]}

May, Anne M. ^{[3
]}

Mol, Linda ^{[2
]}

Hamers, Patricia A. H. ^{[1
]}

Bakker, Sandra D. ^{[4
]}

Creemers, Geert-Jan ^{[5
]}

de Groot, Jan Willem B. ^{[6
]}

de Klerk, Gerty J. ^{[7
]}

Haberkorn, Brigitte C. M. ^{[8
]}

Haringhuizen, Annebeth W. ^{[9
]}

Hoekstra, Ronald ^{[10
]}

Hunting, J. Cornelis B. ^{[11
]}

Kerver, Emile D. ^{[12
]}

Mathijssen-van Stein, Danielle ^{[13
]}

Polee, Marco B. ^{[14
]}

Pruijt, Johannes F. M. ^{[15
]}

Quarles van Ufford-Mannesse, Patricia ^{[16
]}

Radema, Sandra ^{[17
]}

Rietbroek, Ronald C. ^{[18
]}

Simkens, Lieke H. J. ^{[19
]}

Tanis, Bea C. ^{[20
]}

ten Bokkel Huinink, Daan ^{[21
]}

Tjin-A-Ton, Manuel L. R. ^{[22
]}

Tromp-van Driel, Cathrien S. ^{[23
]}

Troost, Monique M. ^{[24
]}

van de Wouw, Agnes J. ^{[25
]}

van den Berkmortel, Franchette W. P. J. ^{[26
]}

van der Pas, Anke J. M. ^{[27
]}

van der Velden, Ankie M. T. ^{[28
]}

van Dijk, Marjan A. ^{[29
]}

van Dodewaard-de Jong, Joyce M. ^{[30
]}

van Druten, Edith B. ^{[31
]}

van Voorthuizen, Theo ^{[32
]}

Jan Veldhuis, Gerrit ^{[33
]}

Verheul, Henk M. W. ^{[34
]}

Vestjens, Hanneke J. H. M. J. ^{[25
]}

Vincent, Jeroen ^{[35
]}

Kranenburg, Onno W. ^{[36
,37
]}

Punt, Cornelis J. A. ^{[38
]}

Vink, Geraldine R. ^{[1
,2
]}

Roodhart, Jeanine M. L. ^{[1
]}

Koopman, Miriam ^{[1
]}

机构：

[1] Univ Utrecht, Univ Med Ctr Utrecht, Dept Med Oncol, Univ Weg 100, NL-3584 CG Utrecht, Netherlands

[2] Netherlands Comprehens Canc Org, Dept Res, Postbus 19079, NL-3501 DB Utrecht, Netherlands

[3] Univ Utrecht, Univ Med Ctr Utrecht, Julius Ctr Hlth Sci & Primary Care, POB 85500, NL-3508 GA Utrecht, Netherlands

[4] Zaans Med Ctr, Dept Med Onco, Postbus 210, NL-1500 EE Zaandam, Netherlands

[5] Catharina Hosp, Dept Med Oncol, Postbus 1350, NL-5602 ZA Eindhoven, Netherlands

[6] Isala Hosp, Dept Med Oncol, Dokter Heesweg 2, NL-8025 AB Zwolle, Netherlands

[7] Spaarne Gasthuis, Dept Med Oncol, Spaarnepoort 1, NL-2134 TM Hoofddorp, Netherlands

[8] Maasstad Hosp, Dept Med Oncol, Postbus 9100, NL-3007 AC Rotterdam, Netherlands

[9] Hosp Gelderse Vallei, Dept Med Oncol, Willy Brandtlaan 10, NL-6716 RP Ede, Netherlands

[10] Ziekenhuisgroep Twente, Dept Med Oncol, Postbus 7600, NL-7600 SZ Almelo, Netherlands

[11] Antonius Hosp, Dept Med Oncol, Postbus 2500, NL-3430 EM Nieuwegein, Netherlands

[12] OLVG, Dept Med Oncol, Oosterpark 9, NL-1091 AC Amsterdam, Netherlands

[13] Franciscus Gasthuis & Vlietland, Dept Med Oncol, Vlietlandpl, NL-3118 JH Schiedam, Netherlands

[14] Med Ctr Leeuwarden, Dept Med Oncol, Postbus 888, NL-8901 BR Leeuwarden, Netherlands

[15] Jeroen Bosch Hosp, Dept Med Oncol, Postbus 90153, NL-5200 ME Shertogenbosch, Netherlands

[16] HagaZiekenhuis, Dept Med Oncol, Els Borst Eilerspl 275, NL-2545 AA The Hague, Netherlands

[17] Radboud Univ Nijmegen, Dept Med Oncol, Med Ctr, Postbus 9101, NL-6500 HB Nijmegen, Netherlands

[18] Rode Kruis Hosp, Dept Med Oncol, Postbus 1074, NL-1940 EB Beverwijk, Netherlands

[19] Maxima Med Ctr, Dept Med Oncol, Postbus 90052, NL-5600 PD Eindhoven, Netherlands

[20] Groene Hart Hosp, Dept Med Oncol, Bleulandweg 10, NL-2803 HH Gouda, Netherlands

[21] Diakonessenhuis Utrecht, Dept Med Oncol, Postbus 80250, NL-3508 TG Utrecht, Netherlands

[22] Hosp Rivierenland, Dept Med Oncol, President Kennedylaan 1, NL-4002 WP Tiel, Netherlands

[23] Gelre Hosp, Dept Med Oncol, Postbus 9014, NL-7300 DS Apeldoorn, Netherlands

[24] Bravis Hosp Bergen Zoom, Dept Med Oncol, Postbus 999, NL-4700 AZ Roosendaal, Netherlands

[25] VieCuri Med Ctr, Dept Med Oncol, Postbus 1926, NL-5900 BX Venlo, Netherlands

[26] Zuyderland Med Ctr Heerlen, Dept Med Oncol, Postbus 5500, NL-6130 MB Geleen, Netherlands

[27] LangeLand Hosp, Dept Med Oncol, Postbus 3015, NL-2700 KJ Zoetermeer, Netherlands

[28] Tergooi, Dept Med Oncol, Riebeeckweg 212, NL-1213 XZ Hilversum, Netherlands

[29] ZorgSaam Hosp, Dept Med Oncol, Wielingenlaan 2, NL-4535 PA Terneuzen, Netherlands

[30] Meander Med Ctr, Dept Med Oncol, Postbus 1502, NL-3800 BM Amersfoort, Netherlands

[31] Reinier Graaf Gasthuis, Dept Med Oncol, Postbus 5011, NL-2600 GA Delft, Netherlands

[32] Hosp Rijnstate, Dept Med Oncol, Wagnerlaan 55, NL-6815 AD Arnhem, Netherlands

[33] Antonius Hosp Sneek, Dept Med Oncol, Postbus 20000, NL-8600 BA Sneek, Netherlands

[34] Univ Amsterdam, Med Ctr, Dept Med Oncol, Box 7057, NL-1007 MB Amsterdam, Netherlands

[35] Elkerliek Hosp, Dept Med Oncol, Postbus 98, NL-5700 AB Helmond, Netherlands

[36] Univ Utrecht, Univ Med Ctr Utrecht, Dept Surg Oncol, Postbus 98, NL-5700 AB Utrecht, Netherlands

[37] Univ Utrecht, Univ Med Ctr Utrecht, Utrecht Platform Organoid Technol, Postbus 98, NL-5700 AB Utrecht, Netherlands

[38] Univ Amsterdam, Med Centers, Dept Med Oncol, Postbus 22660, Amsterdam, Netherlands

来源：

BRITISH JOURNAL OF CANCER | 2021年 / 124卷 / 02期

关键词：

MICROSATELLITE INSTABILITY; POOLED ANALYSIS; BRAF MUTATION; PHASE-III; CAPECITABINE; OXALIPLATIN; MULTICENTER; BEVACIZUMAB; NIVOLUMAB; PROGNOSIS;

D O I：

10.1038/s41416-020-01076-0

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background Metastatic colorectal cancer patients with deficient mismatch repair (dMMR mCRC) benefit from immunotherapy. Interpretation of the single-arm immunotherapy trials is complicated by insignificant survival data during systemic non-immunotherapy. We present survival data on a large, comprehensive cohort of dMMR mCRC patients, treated with or without systemic non-immunotherapy. Methods Two hundred and eighty-one dMMR mCRC patients (n = 54 from three prospective Phase 3 CAIRO trials;n = 227 from the Netherlands Cancer Registry). Overall survival was analysed from diagnosis of mCRC (OS), from initiation of first-line (OS1) and second-line (OS2) systemic treatment. Cox regression analysis examined prognostic factors. As comparison for OS 2746 MMR proficient mCRC patients were identified. Results Of 281 dMMR patients, 62% received first-line and 26% second-line treatment. Median OS was 16.0 months (13.8-19.6) with antitumour therapy and 2.5 months (1.8-3.5) in untreated patients. OS1 was 12.8 months (10.7-15.2) and OS2 6.2 months (5.4-8.9) in treated dMMR patients. Treated dMMR patients had a 7.6-month shorter median OS than pMMR patients. Conclusion Available data from immunotherapy trials lack a control arm with standard systemic treatment. Given the poor outcome compared to the immunotherapy results, our data strongly suggest a survival benefit of immunotherapy in dMMR mCRC patients.

引用

页码：399 / 406

页数：8

共 50 条

[21] ASO Author Reflections: Mismatch Repair and Survival in Metastatic Colorectal Cancer
Scott K. Sherman
Carlos H. F. Chan
Annals of Surgical Oncology, 2020, 27 : 5084 - 5085
[22] ASO Author Reflections: Mismatch Repair and Survival in Metastatic Colorectal Cancer
Sherman, Scott K.
Chan, Carlos H. F.
ANNALS OF SURGICAL ONCOLOGY, 2020, 27 (13) : 5084 - 5085
[23] Response to Chemotherapy and Prognosis in Metastatic Colorectal Cancer With DNA Deficient Mismatch Repair
Alex, Alexandra Khichfy
Siqueira, Sheila
Coudry, Renata
Santos, Juliana
Alves, Michel
Hoff, Paulo M.
Riechelmann, Rachel P.
CLINICAL COLORECTAL CANCER, 2017, 16 (03) : 228 - 239
[24] Immunotherapy in mismatch repair-deficient metastatic colorectal cancer: Long-term outcome and novel predictive markers
Stemmer, A.
Margalit, O.
Serpas, V.
Strauss, G. Z.
Thomas, J.
Shash, P.
Levanon, K.
Shmueli, E. Shacham
Kopetz, E. S.
Overman, M. J.
Boursi, B.
ANNALS OF ONCOLOGY, 2023, 34 : S447 - S447
[25] Immunotherapy in Colorectal Cancer With Mismatch Repair Deficiency
Overman, Michael J.
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2019, 17 (05) : 265 - 267
[26] Immunotherapy efficacy on mismatch repair-deficient colorectal cancer: From bench to bedside
Lizardo, Darleny Y.
Kuang, Chaoyuan
Hao, Suisui
Yu, Jian
Huang, Yi
Zhang, Lin
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER, 2020, 1874 (02):
[27] Immunotherapy Progress in Mismatch Repair-Deficient Colorectal Cancer and Future Therapeutic Challenges
Link, James T.
Overman, Michael James
CANCER JOURNAL, 2016, 22 (03): : 190 - 195
[28] Universal testing of colorectal cancer for deficient mismatch repair - a new era has arrived
Clark, Sue
COLORECTAL DISEASE, 2017, 19 (09) : 801 - 802
[29] Clinicopathological characteristics and outcomes of patients with deficient mismatch repair colorectal cancer
Vinal, David
Martinez-Perez, Daniel
Martinez-Recio, Sergio
Ruiz, Iciar
Bou, Diego Jimenez
Pena, Jesus
Martin-Montalvo, Gema
Rueda-Lara, Antonio
Alameda, Maria
Sainz, Laura Gutierrez
Custodio, Ana B.
Palacios, Maria Elena
Ghanem, Ismael
Salas, Nuria Rodriguez
Feliu, Jaime
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
[30] Deficient mismatch repair system in patients with sporadic advanced colorectal cancer
Koopman, M.
Kortman, G. A. M.
Mekenkamp, L.
Ligtenberg, M. J. L.
Hoogerbrugge, N.
Antonini, N. F.
Punt, C. J. A.
van Krieken, J. H. J. M.
BRITISH JOURNAL OF CANCER, 2009, 100 (02) : 266 - 273

← 1 2 3 4 5 →